Quoin Pharmaceuticals Ltd. Adjustments For Finance Costs
Quoin Pharmaceuticals Ltd. (QNRX) reported Adjustments For Finance Costs of ILS 25.00 thousand for the 6-month period ending 2021-06-30, per its 6-K filed 2021-08-24.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:AdjustmentsForFinanceCosts · last filed 2021-08-24
ILS
| Period end | Adjustments For Finance Costs 6 month | Adjustments For Finance Costs 12 month |
|---|---|---|
| 2021-06-30 | 25.00K ILS 6-K · filed 2021-08-24 | |
| 2020-06-30 | 37.00K ILS 6-K · filed 2021-08-24 | |
| 2019-06-30 | 815.00K ILS 6-K/A · filed 2021-02-11 | |
| 2018-06-30 | -837.00K ILS 6-K · filed 2019-08-13 | |
| 2017-12-31 | 532.00K ILS 20-F · filed 2018-03-19 | |
| 2017-06-30 | 533.00K ILS 6-K · filed 2018-08-09 | |
| 2016-12-31 | 134.00K ILS 20-F · filed 2018-03-19 | |
| 2015-12-31 | 69.00K ILS 20-F · filed 2018-03-19 |
USD
| Period end | Adjustments For Finance Costs 6 month | Adjustments For Finance Costs 12 month |
|---|---|---|
| 2021-06-30 | $8.00K 6-K · filed 2021-08-24 | |
| 2018-06-30 | -$229.00K 6-K · filed 2018-08-09 | |
| 2017-12-31 | $154.00K 20-F · filed 2018-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |